Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of Zostavax at minimum potency in adults ≥50 years
2007-006532-66Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jan 2008
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoster vaccine, live in herpes zoster (HZ), sponsored by Sanofi. Primary endpoints: VZV antibody fold rise at 4 weeks and Safety profile. Started Jan 2008; status: completed.
02
Drugs
zoster vaccine, live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on 2007-006532-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006532-66.